Table 2 Associations of SF3B1 mutation... | American Society of Hematology

Table 2

Associations of SF3B1 mutation in patients with CLL and MDS

Disease	Initial discovery of association, reference	Association with a disease subtype	Further clinical associations	Clonal status
CLL	2	del(11q)^2,6	• Shorter treatment-free or overall survival^3,4,6,7,18	Predominantly subclonal: likely a later event¹⁹
	3		• Faster disease progression^2,4,5,18
	4		• Fludarabine refractoriness³
MDS	10	Refractory anemia with ring sideroblasts^10,11,20-22	• Longer event-free or overall survival^11,21-23	Predominantly clonal: likely an earlier event²¹
MDS	11	Refractory anemia with ring sideroblasts^10,11,20-22	• Lower risk of evolution into AML²¹	Predominantly clonal: likely an earlier event²¹

Disease	Initial discovery of association, reference	Association with a disease subtype	Further clinical associations	Clonal status
CLL	2	del(11q)^2,6	• Shorter treatment-free or overall survival^3,4,6,7,18	Predominantly subclonal: likely a later event¹⁹
	3		• Faster disease progression^2,4,5,18
	4		• Fludarabine refractoriness³
MDS	10	Refractory anemia with ring sideroblasts^10,11,20-22	• Longer event-free or overall survival^11,21-23	Predominantly clonal: likely an earlier event²¹
MDS	11	Refractory anemia with ring sideroblasts^10,11,20-22	• Lower risk of evolution into AML²¹	Predominantly clonal: likely an earlier event²¹